Parkinson's Plus

Reading File

Finding Sources

Searching PubMed

"Parkinson-plus" OR "atypical parkinsonian" syndromes

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive material. Let me compile the full, detailed answer.

Parkinson's Plus Syndromes (Atypical Parkinsonian Syndromes)

Parkinson's Plus (P+) syndromes are a group of neurodegenerative disorders that share the cardinal features of parkinsonism (bradykinesia, rigidity, postural instability) but differ from idiopathic Parkinson's disease (PD) in three key ways:

They involve pathological changes beyond the dopaminergic nigrostriatal pathway
They carry additional clinical features that are not typical of PD
They are minimally or unsustainably responsive to levodopa - because the post-synaptic striatal neurons are themselves degenerated

Robbins & Cotran Pathologic Basis of Disease (p. 1185)
Goldman-Cecil Medicine (p. 3965)

Classification Overview

The main P+ syndromes fall into two molecular categories:

Molecular Basis	Disorders
Tauopathies	Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Synucleinopathies	Multiple System Atrophy (MSA), Dementia with Lewy Bodies (DLB)

Note: DLB is sometimes listed separately as it overlaps heavily with PD pathology; some classifications also include Frontotemporal Dementia with Parkinsonism.

1. Progressive Supranuclear Palsy (PSP)

Pathology: Tau-containing inclusions (globular tangles, distinct from the filamentous tangles in Alzheimer's) in neurons and glia. Greatest burden in the brainstem and deep gray matter - globus pallidus, subthalamic nucleus, substantia nigra, colliculi, and dentate nucleus. Classified as FTLD-tau.

Clinical Features:

Vertical gaze palsy (especially downward - the hallmark) - supranuclear in origin
Truncal rigidity (axial > appendicular), with characteristic retrocollis (neck extended backward, unlike PD's antecollis)
Early postural instability with falls (within the first year - a red flag against PD)
Progressive frontotemporal dementia
Pseudobulbar palsy - dysarthria, dysphagia (often early and prominent)
Monotone, nasal quality of voice (quite distinct from PD's hypokinetic dysarthria)
Apraxia of eyelid opening
Onset: 5th-7th decade; males ~2x more frequent than females
Prognosis: fatal within 5-7 years of onset
Bradley and Daroff's Neurology in Clinical Practice

2. Corticobasal Degeneration (CBD)

Pathology: Tauopathy (same tau gene variants as PSP, but CBD has a greater fraction of tau inclusions in the cerebral cortex, especially motor, premotor, and anterior parietal lobes). "Ballooned" neurons, tufted astrocytes, astrocytic plaques, and tau-positive threads are characteristic. Also classified as FTLD-tau.

Clinical Features:

Asymmetric (often markedly unilateral) extrapyramidal rigidity and motor disturbances
Alien limb phenomenon - the patient feels one limb is not under their control
Apraxia (ideomotor or limb-kinetic) - impaired higher cortical function
Myoclonus (jerking movements of limbs), stimulus-sensitive
Cortical sensory loss, neglect
Cognitive decline (typically later in the illness)
Cortical reflex myoclonus and markedly reduced SICI on TMS studies
Robbins & Cotran Pathologic Basis of Disease (p. 1185)

3. Multiple System Atrophy (MSA)

Pathology: Synucleinopathy - the hallmark is α-synuclein inclusions in the cytoplasm of oligodendrocytes (glial cytoplasmic inclusions, GCIs). Unlike PD, the histopathologic changes are primarily glial rather than neuronal. Three neuroanatomic circuits are affected:

Circuit Affected	Clinical Manifestation
Striatonigral	Parkinsonism (MSA-P)
Olivopontocerebellar	Cerebellar ataxia (MSA-C)
Autonomic nervous system	Orthostatic hypotension, bladder/bowel/sexual dysfunction

Subtypes:

MSA-P (parkinsonian type, formerly striatonigral degeneration): more common in Europeans (~58%)
MSA-C (cerebellar type, formerly olivopontocerebellar atrophy): more common in Japanese (~84%)
(Shy-Drager syndrome was formerly used for the autonomic-predominant variant)

Clinical Features:

Autonomic dysfunction: orthostatic hypotension (drop ≥30 mmHg systolic or ≥15 mmHg diastolic on standing), erectile dysfunction, urinary/GI symptoms
No classic rest tremor (unlike PD)
L-dopa non-responsive parkinsonism that progresses faster than PD
REM sleep behavior disorder (RBD) - strongly associated
Cerebellar signs (ataxia, nystagmus) in MSA-C
Pyramidal signs, stridor (inspiratory stridor is an important clue), dysarthria
Orofacial dystonia, dysphagia
"Whiny" high-pitched voice with sighing/respiratory gasps suggests MSA
Dementia is a red flag against MSA diagnosis
Mean onset age: 54 years; mean survival: ~5.7 years from symptom onset

Neuroimaging:

MSA-C: Atrophy of pons, cerebellum, middle cerebellar peduncles; "hot cross bun" sign (cruciform T2-hyperintensity in pons)
MSA-P: T2-hyperintensity of lateral putaminal rim or hypointensity of posterior putamen
Bradley and Daroff's Neurology in Clinical Practice

4. Dementia with Lewy Bodies (DLB)

Pathology: Lewy bodies (α-synuclein + ubiquitin inclusions) in limbic and cortical structures - the same α-synuclein molecular fold as in PD. Approximately 80% of DLB patients have additional Alzheimer pathology.

Clinical Features (2017 DLB Consortium Fourth Consensus Criteria):

Core features (early onset, persist throughout):

Fluctuating cognition with pronounced variations in attention and alertness
Recurrent visual hallucinations - typically well-formed and detailed (e.g., people, animals)
REM sleep behavior disorder (RBD) - may precede cognitive decline by years
Spontaneous cardinal features of parkinsonism (bradykinesia, rest tremor, rigidity)

Supportive features:

Severe neuroleptic sensitivity (antipsychotics can cause catastrophic worsening)
Postural instability, repeated falls, syncope
Severe autonomic dysfunction
Hyposmia, hypersomnia, depression, anxiety

Indicative biomarkers:

Reduced dopamine transporter uptake (DaT-SPECT)
Abnormal ¹²³I-MIBG myocardial scintigraphy (low uptake)
Polysomnographic REM sleep without atonia

PD dementia (PDD) vs. DLB: The key distinguishing feature is timing - if motor symptoms precede dementia by >1 year, the diagnosis is PDD; if dementia occurs simultaneously or precedes motor symptoms, it is DLB.

Goldman-Cecil Medicine; Kaplan & Sadock's Comprehensive Textbook of Psychiatry

Key Differentiating Features at a Glance

Feature	PD	PSP	CBD	MSA	DLB
Levodopa response	Good	Poor	Poor	Poor	Poor
Tremor	Rest tremor (classic)	Rare	Rare	Rare	Rest tremor (variable)
Falls	Late	Early (year 1)	Late	Moderate	Early-moderate
Eye movements	Mild impairment	Downward gaze palsy	Variable	Oculomotor abnormalities	Variable
Asymmetry	Asymmetric	Symmetric	Very asymmetric	Variable	Variable
Dementia	Late	Mid-late	Mid-late	Rare/red flag	Early, prominent
Autonomic	Mild-moderate	Mild	Mild	Severe	Moderate
Hallucinations	Drug-induced	Rare	Rare	Rare	Prominent (core feature)
Molecular	α-synuclein (Lewy bodies, neuronal)	Tau (globular tangles)	Tau (astrocytic plaques)	α-synuclein (glial GCIs)	α-synuclein (Lewy bodies, cortical)

Shared "Red Flags" Against Idiopathic PD

The following features should prompt consideration of a P+ syndrome:

Early falls (within 1 year of onset)
Early or prominent dysarthria/dysphagia
Symmetrical onset
Absent rest tremor
Poor or no response to levodopa
Early autonomic failure
Early cognitive impairment or dementia
Vertical gaze palsy
Alien limb or apraxia
Bradley and Daroff's Neurology in Clinical Practice; Goldman-Cecil Medicine

Recent Literature (2024-2025)

A 2024 consensus review - A General Neurologist's Practical Diagnostic Algorithm for Atypical Parkinsonian Disorders (Neurol Clin Pract, 2024; PMID 39185098) - proposed structured diagnostic algorithms to help non-specialist neurologists systematically distinguish between PSP, CBD, MSA, and DLB in clinical practice.

A 2024 imaging review - Atypical Parkinsonian Syndromes: Structural, Functional, and Molecular Imaging Features (AJNR, 2024; PMID 39209485) - summarizes MRI, PET, and SPECT biomarkers for each P+ syndrome, including the hot cross bun sign in MSA, hummingbird/penguin sign in PSP, and DaT-SPECT findings.

Create a diagnostic flowchart document comparing Parkinson-plus syndromes

Reading File

Running Command

ls /home/daytona/workspace/ 2>/dev/null && ls /home/daytona/skills/docx/scripts/…

Running Command

mkdir -p /home/daytona/workspace/parkinson-plus && node -e "require('docx'); con…

Writing File

~/parkinson-plus/generate.js

const {
  Document, Packer, Paragraph, TextRun, Table, TableRow, TableCell,
  AlignmentType, HeadingLevel, BorderStyle, WidthType, ShadingType,
  VerticalAlign, PageOrientation, Header, Footer, PageNumber,
  NumberFormat
} = require('docx');
const fs = require('fs');

// ── Colour palette ──────────────────────────────────────────────────────────
const COLORS = {
  headerBg:    '1B3A6B',   // deep navy
  headerText:  'FFFFFF',
  subheaderBg: '2E6DA4',   // medium blue
  psp:         'D6EAF8',   // light blue
  cbd:         'D5F5E3',   // light green
  msa:         'FEF9E7',   // light yellow
  dlb:         'FDEDEC',   // light red/pink
  pspDark:     '2980B9',
  cbdDark:     '27AE60',
  msaDark:     'F39C12',
  dlbDark:     'E74C3C',
  flowBg:      'EBF5FB',
  redFlag:     'FADBD8',
  neutral:     'F2F3F4',
  border:      'BDC3C7',
  textDark:    '1A1A2E',
  accent:      'E8F4FD',
};

// ── Helpers ─────────────────────────────────────────────────────────────────
const noBorder = { style: BorderStyle.NONE, size: 0, color: 'FFFFFF' };
const thinBorder = (color) => ({ style: BorderStyle.SINGLE, size: 4, color: color || COLORS.border });

function cell(text, { bg, bold, color, align, vAlign, colSpan, width, size, italic } = {}) {
  return new TableCell({
    columnSpan: colSpan || 1,
    width: width ? { size: width, type: WidthType.DXA } : undefined,
    verticalAlign: vAlign || VerticalAlign.CENTER,
    shading: bg ? { type: ShadingType.SOLID, color: bg } : undefined,
    borders: {
      top: thinBorder(COLORS.border),
      bottom: thinBorder(COLORS.border),
      left: thinBorder(COLORS.border),
      right: thinBorder(COLORS.border),
    },
    children: [
      new Paragraph({
        alignment: align || AlignmentType.LEFT,
        spacing: { before: 60, after: 60 },
        children: [
          new TextRun({
            text: text,
            bold: bold || false,
            color: color || COLORS.textDark,
            size: size || 18,
            font: 'Calibri',
            italics: italic || false,
          }),
        ],
      }),
    ],
  });
}

function headerCell(text, colSpan, bg) {
  return cell(text, {
    bg: bg || COLORS.headerBg,
    bold: true,
    color: COLORS.headerText,
    align: AlignmentType.CENTER,
    colSpan: colSpan || 1,
    size: 20,
  });
}

function sectionTitle(text, level, color) {
  return new Paragraph({
    heading: level || HeadingLevel.HEADING_1,
    spacing: { before: 240, after: 100 },
    children: [
      new TextRun({
        text,
        bold: true,
        color: color || COLORS.headerBg,
        size: level === HeadingLevel.HEADING_2 ? 26 : 32,
        font: 'Calibri',
      }),
    ],
  });
}

function bodyPara(text, opts = {}) {
  return new Paragraph({
    spacing: { before: 40, after: 40 },
    alignment: opts.align || AlignmentType.LEFT,
    children: [
      new TextRun({
        text,
        size: opts.size || 18,
        font: 'Calibri',
        color: opts.color || COLORS.textDark,
        bold: opts.bold || false,
        italics: opts.italic || false,
      }),
    ],
  });
}

function blankLine() {
  return new Paragraph({ children: [new TextRun({ text: '', size: 14 })] });
}

function flowBox(label, subtext, bg, borderColor) {
  return new Table({
    width: { size: 8000, type: WidthType.DXA },
    borders: {
      top: thinBorder(borderColor), bottom: thinBorder(borderColor),
      left: thinBorder(borderColor), right: thinBorder(borderColor),
      insideH: noBorder, insideV: noBorder,
    },
    rows: [
      new TableRow({
        children: [
          new TableCell({
            shading: { type: ShadingType.SOLID, color: bg },
            borders: {
              top: thinBorder(borderColor), bottom: thinBorder(borderColor),
              left: thinBorder(borderColor), right: thinBorder(borderColor),
            },
            children: [
              new Paragraph({
                alignment: AlignmentType.CENTER,
                spacing: { before: 80, after: 40 },
                children: [new TextRun({ text: label, bold: true, size: 20, font: 'Calibri', color: COLORS.textDark })],
              }),
              ...(subtext ? [new Paragraph({
                alignment: AlignmentType.CENTER,
                spacing: { before: 0, after: 80 },
                children: [new TextRun({ text: subtext, size: 16, font: 'Calibri', color: '555555', italics: true })],
              })] : []),
            ],
          }),
        ],
      }),
    ],
  });
}

function arrowPara() {
  return new Paragraph({
    alignment: AlignmentType.CENTER,
    spacing: { before: 40, after: 40 },
    children: [new TextRun({ text: '▼', size: 24, color: COLORS.subheaderBg, font: 'Calibri' })],
  });
}

function diamondBox(question, bg) {
  return new Table({
    width: { size: 8000, type: WidthType.DXA },
    rows: [
      new TableRow({
        children: [
          new TableCell({
            shading: { type: ShadingType.SOLID, color: bg || 'EBF5FB' },
            borders: {
              top: thinBorder('2980B9'), bottom: thinBorder('2980B9'),
              left: thinBorder('2980B9'), right: thinBorder('2980B9'),
            },
            children: [
              new Paragraph({
                alignment: AlignmentType.CENTER,
                spacing: { before: 80, after: 80 },
                children: [
                  new TextRun({ text: '◆  ', size: 20, bold: true, color: COLORS.subheaderBg, font: 'Calibri' }),
                  new TextRun({ text: question, size: 19, bold: true, color: COLORS.textDark, font: 'Calibri' }),
                ],
              }),
            ],
          }),
        ],
      }),
    ],
  });
}

// ── SECTION 1: Cover / Title ─────────────────────────────────────────────────
const titleSection = [
  blankLine(),
  new Paragraph({
    alignment: AlignmentType.CENTER,
    spacing: { before: 200, after: 80 },
    children: [
      new TextRun({
        text: "PARKINSON'S PLUS SYNDROMES",
        bold: true, size: 52, color: COLORS.headerBg, font: 'Calibri',
      }),
    ],
  }),
  new Paragraph({
    alignment: AlignmentType.CENTER,
    spacing: { before: 0, after: 60 },
    children: [
      new TextRun({
        text: 'Diagnostic Flowchart & Clinical Comparison',
        size: 30, color: COLORS.subheaderBg, font: 'Calibri', italics: true,
      }),
    ],
  }),
  new Paragraph({
    alignment: AlignmentType.CENTER,
    spacing: { before: 0, after: 240 },
    children: [
      new TextRun({
        text: 'Based on Bradley & Daroff\'s Neurology | Robbins & Cotran | Goldman-Cecil Medicine',
        size: 18, color: '888888', font: 'Calibri',
      }),
    ],
  }),
];

// ── SECTION 2: Flowchart (simulated with tables) ─────────────────────────────
const flowchartSection = [
  sectionTitle('SECTION 1 — DIAGNOSTIC FLOWCHART', HeadingLevel.HEADING_1),
  bodyPara('Use this step-by-step algorithm to differentiate Parkinson\'s Plus syndromes from idiopathic Parkinson\'s Disease (PD).', { size: 18, italic: true }),
  blankLine(),

  // Step 1
  flowBox('STEP 1 — Confirm Parkinsonism', 'Bradykinesia + ≥1 of: rigidity, rest tremor, postural instability', 'D6EAF8', '2980B9'),
  arrowPara(),

  // Decision: Red flags?
  diamondBox('Are RED FLAGS present? (early falls, vertical gaze palsy, alien limb, early severe autonomic failure, poor levodopa response, early dementia)'),
  blankLine(),

  // Red flag table
  new Table({
    width: { size: 9000, type: WidthType.DXA },
    rows: [
      new TableRow({
        children: [
          headerCell('RED FLAG', 1, COLORS.pspDark),
          headerCell('Suggests', 1, COLORS.pspDark),
        ],
      }),
      new TableRow({ children: [cell('Vertical (downward) gaze palsy'), cell('PSP ★')] }),
      new TableRow({ children: [cell('Early falls within year 1, axial rigidity'), cell('PSP')] }),
      new TableRow({ children: [cell('Alien limb phenomenon + apraxia'), cell('CBD ★')] }),
      new TableRow({ children: [cell('Very asymmetric motor signs'), cell('CBD')] }),
      new TableRow({ children: [cell('Severe autonomic failure (orthostasis, stridor)'), cell('MSA ★')] }),
      new TableRow({ children: [cell('Cerebellar ataxia + parkinsonism'), cell('MSA-C')] }),
      new TableRow({ children: [cell('Early fluctuating cognition + vivid hallucinations'), cell('DLB ★')] }),
      new TableRow({ children: [cell('REM sleep behaviour disorder (early)'), cell('DLB / MSA')] }),
      new TableRow({ children: [cell('Severe neuroleptic sensitivity'), cell('DLB')] }),
      new TableRow({ children: [cell('Poor / absent levodopa response'), cell('All P+ syndromes')] }),
    ],
  }),

  blankLine(),
  arrowPara(),

  // Step 3
  flowBox('STEP 2 — Levodopa Trial', 'Assess levodopa responsiveness over 3–6 months', 'FEF9E7', COLORS.msaDark),
  blankLine(),

  new Table({
    width: { size: 9000, type: WidthType.DXA },
    rows: [
      new TableRow({
        children: [
          headerCell('Levodopa Response', 1, COLORS.subheaderBg),
          headerCell('Interpretation', 1, COLORS.subheaderBg),
        ],
      }),
      new TableRow({ children: [cell('Good, sustained (>30% improvement)'), cell('Favours idiopathic PD')] }),
      new TableRow({ children: [cell('Transient or modest response'), cell('PSP (some), DLB')] }),
      new TableRow({ children: [cell('None / worsening'), cell('MSA, CBD, advanced PSP')] }),
    ],
  }),

  blankLine(),
  arrowPara(),

  // Step 4 — Neuroimaging
  flowBox('STEP 3 — Neuroimaging (MRI Brain)', 'Key structural and signal abnormalities', COLORS.flowBg, COLORS.subheaderBg),
  blankLine(),

  new Table({
    width: { size: 9000, type: WidthType.DXA },
    rows: [
      new TableRow({
        children: [
          headerCell('Finding', 1, COLORS.subheaderBg),
          headerCell('Diagnosis Suggested', 1, COLORS.subheaderBg),
        ],
      }),
      new TableRow({ children: [cell('"Hummingbird / Penguin" sign — midbrain atrophy on sagittal MRI'), cell('PSP')] }),
      new TableRow({ children: [cell('"Hot cross bun" sign — cruciform T2 pons hyperintensity'), cell('MSA-C')] }),
      new TableRow({ children: [cell('Lateral putaminal rim T2 hyperintensity; posterior putamen hypointensity'), cell('MSA-P')] }),
      new TableRow({ children: [cell('Asymmetric frontoparietal/perirolandic atrophy'), cell('CBD')] }),
      new TableRow({ children: [cell('Posterior cortical atrophy, diffuse cortical Lewy changes'), cell('DLB')] }),
      new TableRow({ children: [cell('DaT-SPECT: reduced uptake bilateral basal ganglia'), cell('DLB, PD, PSP')] }),
      new TableRow({ children: [cell('¹²³I-MIBG: low myocardial uptake'), cell('DLB (highly specific)')] }),
    ],
  }),
];

// ── SECTION 3: Comparison Table ─────────────────────────────────────────────
const comparisonSection = [
  blankLine(),
  sectionTitle('SECTION 2 — CLINICAL COMPARISON TABLE', HeadingLevel.HEADING_1),
  bodyPara('Comparative clinical, pathological, and investigative features across the four main Parkinson\'s Plus syndromes.', { size: 18, italic: true }),
  blankLine(),

  new Table({
    width: { size: 9500, type: WidthType.DXA },
    rows: [
      // Header row
      new TableRow({
        children: [
          headerCell('Feature', 1, COLORS.headerBg),
          headerCell('PSP', 1, COLORS.pspDark),
          headerCell('CBD', 1, COLORS.cbdDark),
          headerCell('MSA', 1, COLORS.msaDark),
          headerCell('DLB', 1, COLORS.dlbDark),
        ],
      }),
      // Pathology row
      new TableRow({
        children: [
          cell('Molecular basis', { bg: COLORS.neutral, bold: true }),
          cell('Tauopathy (4R tau)', { bg: COLORS.psp }),
          cell('Tauopathy (4R tau)', { bg: COLORS.cbd }),
          cell('α-Synucleinopathy (glial)', { bg: COLORS.msa }),
          cell('α-Synucleinopathy (neuronal)', { bg: COLORS.dlb }),
        ],
      }),
      new TableRow({
        children: [
          cell('Pathological hallmark', { bg: COLORS.neutral, bold: true }),
          cell('Globular tau tangles; tufted astrocytes', { bg: COLORS.psp }),
          cell('Astrocytic plaques; ballooned neurons', { bg: COLORS.cbd }),
          cell('Glial cytoplasmic inclusions (GCIs) in oligodendrocytes', { bg: COLORS.msa }),
          cell('Cortical & limbic Lewy bodies', { bg: COLORS.dlb }),
        ],
      }),
      new TableRow({
        children: [
          cell('Main regions affected', { bg: COLORS.neutral, bold: true }),
          cell('Brainstem, deep grey matter, basal ganglia', { bg: COLORS.psp }),
          cell('Motor/premotor cortex, anterior parietal, SN', { bg: COLORS.cbd }),
          cell('Striatonigral, olivopontocerebellar, autonomic circuits', { bg: COLORS.msa }),
          cell('Limbic, neocortical, SN', { bg: COLORS.dlb }),
        ],
      }),
      // Clinical
      new TableRow({
        children: [
          cell('Onset age', { bg: COLORS.neutral, bold: true }),
          cell('5th–7th decade', { bg: COLORS.psp }),
          cell('6th–7th decade', { bg: COLORS.cbd }),
          cell('~54 years (mean)', { bg: COLORS.msa }),
          cell('7th–8th decade', { bg: COLORS.dlb }),
        ],
      }),
      new TableRow({
        children: [
          cell('Sex predominance', { bg: COLORS.neutral, bold: true }),
          cell('Male 2:1', { bg: COLORS.psp }),
          cell('Equal', { bg: COLORS.cbd }),
          cell('Equal', { bg: COLORS.msa }),
          cell('Slight male', { bg: COLORS.dlb }),
        ],
      }),
      new TableRow({
        children: [
          cell('Motor asymmetry', { bg: COLORS.neutral, bold: true }),
          cell('Symmetric (axial)', { bg: COLORS.psp }),
          cell('Very asymmetric ★', { bg: COLORS.cbd, bold: true }),
          cell('Variable', { bg: COLORS.msa }),
          cell('Variable', { bg: COLORS.dlb }),
        ],
      }),
      new TableRow({
        children: [
          cell('Rest tremor', { bg: COLORS.neutral, bold: true }),
          cell('Rare', { bg: COLORS.psp }),
          cell('Rare / myoclonus', { bg: COLORS.cbd }),
          cell('Rare', { bg: COLORS.msa }),
          cell('Present (variable)', { bg: COLORS.dlb }),
        ],
      }),
      new TableRow({
        children: [
          cell('Early falls', { bg: COLORS.neutral, bold: true }),
          cell('Yes — Year 1 ★', { bg: COLORS.psp, bold: true }),
          cell('Later in course', { bg: COLORS.cbd }),
          cell('Moderate', { bg: COLORS.msa }),
          cell('Early-moderate', { bg: COLORS.dlb }),
        ],
      }),
      new TableRow({
        children: [
          cell('Eye movement abnormality', { bg: COLORS.neutral, bold: true }),
          cell('Vertical (downgaze) palsy ★', { bg: COLORS.psp, bold: true }),
          cell('Variable oculomotor', { bg: COLORS.cbd }),
          cell('Oculomotor abnormalities', { bg: COLORS.msa }),
          cell('Variable', { bg: COLORS.dlb }),
        ],
      }),
      new TableRow({
        children: [
          cell('Characteristic motor sign', { bg: COLORS.neutral, bold: true }),
          cell('Retrocollis; axial > limb rigidity', { bg: COLORS.psp }),
          cell('Alien limb ★; apraxia', { bg: COLORS.cbd }),
          cell('Stridor; orofacial dystonia', { bg: COLORS.msa }),
          cell('Parkinsonism (often mild)', { bg: COLORS.dlb }),
        ],
      }),
      // Autonomic
      new TableRow({
        children: [
          cell('Autonomic dysfunction', { bg: COLORS.neutral, bold: true }),
          cell('Mild', { bg: COLORS.psp }),
          cell('Mild', { bg: COLORS.cbd }),
          cell('Severe ★ (orthostasis, bladder, erectile)', { bg: COLORS.msa, bold: true }),
          cell('Moderate', { bg: COLORS.dlb }),
        ],
      }),
      // Cognitive / Psychiatric
      new TableRow({
        children: [
          cell('Dementia', { bg: COLORS.neutral, bold: true }),
          cell('Frontotemporal, mid-late', { bg: COLORS.psp }),
          cell('Parietal/apraxia, mid-late', { bg: COLORS.cbd }),
          cell('Rare; red flag if present', { bg: COLORS.msa }),
          cell('Early, prominent ★', { bg: COLORS.dlb, bold: true }),
        ],
      }),
      new TableRow({
        children: [
          cell('Visual hallucinations', { bg: COLORS.neutral, bold: true }),
          cell('Rare', { bg: COLORS.psp }),
          cell('Rare', { bg: COLORS.cbd }),
          cell('Rare', { bg: COLORS.msa }),
          cell('Core feature ★ (well-formed)', { bg: COLORS.dlb, bold: true }),
        ],
      }),
      new TableRow({
        children: [
          cell('Cognitive fluctuations', { bg: COLORS.neutral, bold: true }),
          cell('Absent', { bg: COLORS.psp }),
          cell('Absent', { bg: COLORS.cbd }),
          cell('Absent', { bg: COLORS.msa }),
          cell('Core feature ★', { bg: COLORS.dlb, bold: true }),
        ],
      }),
      new TableRow({
        children: [
          cell('REM sleep behaviour disorder', { bg: COLORS.neutral, bold: true }),
          cell('Absent', { bg: COLORS.psp }),
          cell('Absent', { bg: COLORS.cbd }),
          cell('Strongly associated', { bg: COLORS.msa }),
          cell('Core feature ★', { bg: COLORS.dlb, bold: true }),
        ],
      }),
      // Treatment
      new TableRow({
        children: [
          cell('Levodopa response', { bg: COLORS.neutral, bold: true }),
          cell('Poor (some transient benefit)', { bg: COLORS.psp }),
          cell('Poor', { bg: COLORS.cbd }),
          cell('None (MSA-P) / None (MSA-C)', { bg: COLORS.msa }),
          cell('Partial; may worsen psychosis', { bg: COLORS.dlb }),
        ],
      }),
      new TableRow({
        children: [
          cell('Neuroleptic sensitivity', { bg: COLORS.neutral, bold: true }),
          cell('Moderate', { bg: COLORS.psp }),
          cell('Moderate', { bg: COLORS.cbd }),
          cell('Moderate', { bg: COLORS.msa }),
          cell('SEVERE ★ (catastrophic)', { bg: COLORS.dlb, bold: true }),
        ],
      }),
      // Imaging
      new TableRow({
        children: [
          cell('Key MRI finding', { bg: COLORS.neutral, bold: true }),
          cell('Hummingbird / penguin sign (midbrain atrophy)', { bg: COLORS.psp }),
          cell('Asymmetric frontoparietal atrophy', { bg: COLORS.cbd }),
          cell('Hot cross bun sign (MSA-C); putaminal changes (MSA-P)', { bg: COLORS.msa }),
          cell('Posterior cortical atrophy; normal/mild changes', { bg: COLORS.dlb }),
        ],
      }),
      new TableRow({
        children: [
          cell('DaT-SPECT', { bg: COLORS.neutral, bold: true }),
          cell('Reduced', { bg: COLORS.psp }),
          cell('Reduced', { bg: COLORS.cbd }),
          cell('Reduced', { bg: COLORS.msa }),
          cell('Reduced ★ (indicative biomarker)', { bg: COLORS.dlb }),
        ],
      }),
      new TableRow({
        children: [
          cell('MIBG scintigraphy', { bg: COLORS.neutral, bold: true }),
          cell('Normal', { bg: COLORS.psp }),
          cell('Normal', { bg: COLORS.cbd }),
          cell('Normal', { bg: COLORS.msa }),
          cell('Low uptake ★ (indicative biomarker)', { bg: COLORS.dlb, bold: true }),
        ],
      }),
      // Prognosis
      new TableRow({
        children: [
          cell('Mean survival from onset', { bg: COLORS.neutral, bold: true }),
          cell('5–7 years', { bg: COLORS.psp }),
          cell('6–8 years', { bg: COLORS.cbd }),
          cell('~5.7 years', { bg: COLORS.msa }),
          cell('Variable (5–8 years from dementia)', { bg: COLORS.dlb }),
        ],
      }),
    ],
  }),
];

// ── SECTION 4: Individual Syndrome Summaries ─────────────────────────────────
const summarySection = [
  blankLine(),
  sectionTitle('SECTION 3 — INDIVIDUAL SYNDROME PROFILES', HeadingLevel.HEADING_1),

  // PSP
  sectionTitle('Progressive Supranuclear Palsy (PSP)', HeadingLevel.HEADING_2, COLORS.pspDark),
  new Table({
    width: { size: 9000, type: WidthType.DXA },
    rows: [
      new TableRow({ children: [
        cell('Pathology', { bg: COLORS.neutral, bold: true, width: 2200 }),
        cell('4R tauopathy. Globular tangles in brainstem/deep grey matter. Tufted astrocytes, coiled bodies. Classified as FTLD-tau.', { bg: COLORS.psp }),
      ]}),
      new TableRow({ children: [
        cell('Core clinical triad', { bg: COLORS.neutral, bold: true }),
        cell('(1) Supranuclear vertical gaze palsy  (2) Axial rigidity with retrocollis  (3) Early falls (year 1)', { bg: COLORS.psp }),
      ]}),
      new TableRow({ children: [
        cell('Other features', { bg: COLORS.neutral, bold: true }),
        cell('Pseudobulbar palsy (dysarthria, dysphagia), frontal dementia, apraxia of eyelid opening, monotone/nasal voice, hypophonia, palilalia', { bg: COLORS.psp }),
      ]}),
      new TableRow({ children: [
        cell('Epidemiology', { bg: COLORS.neutral, bold: true }),
        cell('5th–7th decade onset; males 2× more than females; fatal within 5–7 years', { bg: COLORS.psp }),
      ]}),
      new TableRow({ children: [
        cell('Management', { bg: COLORS.neutral, bold: true }),
        cell('No disease-modifying therapy. Levodopa trial (partial/transient benefit in ~30%). Fall prevention critical. Speech/swallowing therapy.', { bg: COLORS.psp }),
      ]}),
    ],
  }),
  blankLine(),

  // CBD
  sectionTitle('Corticobasal Degeneration (CBD)', HeadingLevel.HEADING_2, COLORS.cbdDark),
  new Table({
    width: { size: 9000, type: WidthType.DXA },
    rows: [
      new TableRow({ children: [
        cell('Pathology', { bg: COLORS.neutral, bold: true, width: 2200 }),
        cell('4R tauopathy (same tau gene variants as PSP). Tau inclusions predominantly in cortex. Astrocytic plaques, ballooned neurons (chromatolytic). Classified as FTLD-tau.', { bg: COLORS.cbd }),
      ]}),
      new TableRow({ children: [
        cell('Core clinical triad', { bg: COLORS.neutral, bold: true }),
        cell('(1) Alien limb phenomenon  (2) Asymmetric extrapyramidal rigidity + apraxia  (3) Cortical sensory loss / myoclonus', { bg: COLORS.cbd }),
      ]}),
      new TableRow({ children: [
        cell('Other features', { bg: COLORS.neutral, bold: true }),
        cell('Stimulus-sensitive myoclonus, limb dystonia, action tremor, parietal neglect, later frontal dementia. Very asymmetric onset is key.', { bg: COLORS.cbd }),
      ]}),
      new TableRow({ children: [
        cell('Key distinction from PSP', { bg: COLORS.neutral, bold: true }),
        cell('CBD is more asymmetric and cortical (apraxia prominent); PSP is more axial and brainstem (downgaze palsy)', { bg: COLORS.cbd }),
      ]}),
      new TableRow({ children: [
        cell('Management', { bg: COLORS.neutral, bold: true }),
        cell('No disease-modifying therapy. Levodopa rarely helpful. Clonazepam for myoclonus. OT/PT for apraxia.', { bg: COLORS.cbd }),
      ]}),
    ],
  }),
  blankLine(),

  // MSA
  sectionTitle('Multiple System Atrophy (MSA)', HeadingLevel.HEADING_2, COLORS.msaDark),
  new Table({
    width: { size: 9000, type: WidthType.DXA },
    rows: [
      new TableRow({ children: [
        cell('Pathology', { bg: COLORS.neutral, bold: true, width: 2200 }),
        cell('α-Synucleinopathy. Glial cytoplasmic inclusions (GCIs) in oligodendrocytes. Primarily white matter/glial changes. Three circuits: striatonigral (MSA-P), olivopontocerebellar (MSA-C), autonomic.', { bg: COLORS.msa }),
      ]}),
      new TableRow({ children: [
        cell('Subtypes', { bg: COLORS.neutral, bold: true }),
        cell('MSA-P (parkinsonian, formerly striatonigral degeneration) — 58% in Europeans\nMSA-C (cerebellar, formerly OPCA) — 84% in Japanese\nShy-Drager syndrome = autonomic-predominant (historical term)', { bg: COLORS.msa }),
      ]}),
      new TableRow({ children: [
        cell('Core clinical features', { bg: COLORS.neutral, bold: true }),
        cell('Autonomic failure (orthostatic hypotension ≥30/15 mmHg, erectile dysfunction, bladder/bowel) + Parkinsonism (MSA-P) OR Cerebellar ataxia (MSA-C)', { bg: COLORS.msa }),
      ]}),
      new TableRow({ children: [
        cell('Other features', { bg: COLORS.neutral, bold: true }),
        cell('RBD, pyramidal signs, stridor (inspiratory — hallmark of respiratory dysfunction), orofacial dystonia, high-pitched whiny voice, no classic rest tremor, no dementia (red flag if present)', { bg: COLORS.msa }),
      ]}),
      new TableRow({ children: [
        cell('Evaluation', { bg: COLORS.neutral, bold: true }),
        cell('Lying/standing BP. Autonomic reflex screen. Thermoregulatory sweat test (anhidrosis). Elevated post-void residual. MRI (hot cross bun sign / putaminal changes).', { bg: COLORS.msa }),
      ]}),
      new TableRow({ children: [
        cell('Management', { bg: COLORS.neutral, bold: true }),
        cell('Fludrocortisone/midodrine for orthostasis. Levodopa trial (rarely useful in MSA-P). Fall prevention. Speech/swallow therapy. CPAP for sleep-disordered breathing.', { bg: COLORS.msa }),
      ]}),
      new TableRow({ children: [
        cell('Prognosis', { bg: COLORS.neutral, bold: true }),
        cell('Mean onset age 54; mean survival ~5.7 years. Incidence 3/100,000 person-years.', { bg: COLORS.msa }),
      ]}),
    ],
  }),
  blankLine(),

  // DLB
  sectionTitle('Dementia with Lewy Bodies (DLB)', HeadingLevel.HEADING_2, COLORS.dlbDark),
  new Table({
    width: { size: 9000, type: WidthType.DXA },
    rows: [
      new TableRow({ children: [
        cell('Pathology', { bg: COLORS.neutral, bold: true, width: 2200 }),
        cell('α-Synucleinopathy (same fold as PD). Lewy bodies in limbic/cortical structures. ~80% also have AD pathology co-existing.', { bg: COLORS.dlb }),
      ]}),
      new TableRow({ children: [
        cell('Core clinical features\n(2017 DLB Consortium)', { bg: COLORS.neutral, bold: true }),
        cell('1. Fluctuating cognition (attention/alertness)\n2. Recurrent vivid visual hallucinations\n3. REM sleep behaviour disorder (may precede dementia by years)\n4. Spontaneous parkinsonism (bradykinesia, rigidity, rest tremor)', { bg: COLORS.dlb }),
      ]}),
      new TableRow({ children: [
        cell('Supportive features', { bg: COLORS.neutral, bold: true }),
        cell('Severe neuroleptic sensitivity (AVOID typical/atypical antipsychotics), postural instability, syncope, autonomic dysfunction, hyposmia, hypersomnia, depression, anxiety', { bg: COLORS.dlb }),
      ]}),
      new TableRow({ children: [
        cell('Indicative biomarkers', { bg: COLORS.neutral, bold: true }),
        cell('↓ DaT-SPECT uptake (basal ganglia)\n↓ ¹²³I-MIBG myocardial scintigraphy uptake\nPolysomnography: REM sleep without atonia', { bg: COLORS.dlb }),
      ]}),
      new TableRow({ children: [
        cell('DLB vs PD Dementia', { bg: COLORS.neutral, bold: true }),
        cell('Motor symptoms precede dementia by >1 year → PD Dementia (PDD)\nDementia precedes or is simultaneous with motor symptoms → DLB\n(The "1-year rule")', { bg: COLORS.dlb }),
      ]}),
      new TableRow({ children: [
        cell('Management', { bg: COLORS.neutral, bold: true }),
        cell('AChEIs (rivastigmine — FDA approved for PDD; used off-label in DLB). Melatonin/clonazepam for RBD. AVOID conventional antipsychotics. Low-dose quetiapine or clozapine if psychosis must be treated.', { bg: COLORS.dlb }),
      ]}),
    ],
  }),
];

// ── SECTION 5: Red Flags Summary ─────────────────────────────────────────────
const redFlagsSection = [
  blankLine(),
  sectionTitle('SECTION 4 — RED FLAGS AGAINST IDIOPATHIC PD', HeadingLevel.HEADING_1),
  bodyPara('The following features at presentation should prompt consideration of a Parkinson\'s Plus syndrome:', { italic: true }),
  blankLine(),

  new Table({
    width: { size: 9000, type: WidthType.DXA },
    rows: [
      new TableRow({ children: [headerCell('Red Flag', 1, COLORS.dlbDark), headerCell('Clinical Significance', 1, COLORS.dlbDark)] }),
      ...([
        ['Early falls within 1 year of onset', 'Suggests PSP; atypical for early PD'],
        ['Vertical (especially downward) gaze palsy', 'Virtually diagnostic of PSP'],
        ['Alien limb phenomenon', 'Hallmark of CBS/CBD'],
        ['Apraxia (limb-kinetic or ideomotor)', 'Suggests CBD'],
        ['Severe orthostatic hypotension at presentation', 'Suggests MSA (or pure autonomic failure)'],
        ['Inspiratory stridor', 'Highly suggestive of MSA'],
        ['Ataxia + parkinsonism combination', 'Suggests MSA-C'],
        ['Early prominent dementia or hallucinations', 'Suggests DLB'],
        ['REM sleep behaviour disorder (early, prodromal)', 'Suggests DLB or MSA'],
        ['Fluctuating consciousness / attention', 'Suggests DLB'],
        ['Symmetric onset', 'Atypical for PD; suggests P+ syndrome'],
        ['Absent rest tremor', 'Less likely idiopathic PD'],
        ['No levodopa response after adequate trial', 'All P+ syndromes; strongly against PD'],
        ['Severe neuroleptic sensitivity', 'Suggests DLB (potentially life-threatening)'],
      ]).map(([flag, sig]) => new TableRow({ children: [cell(flag, { bg: COLORS.redFlag }), cell(sig, { bg: COLORS.neutral })] })),
    ],
  }),
];

// ── SECTION 6: Treatment Summary ─────────────────────────────────────────────
const treatmentSection = [
  blankLine(),
  sectionTitle('SECTION 5 — TREATMENT OVERVIEW', HeadingLevel.HEADING_1),
  blankLine(),

  new Table({
    width: { size: 9500, type: WidthType.DXA },
    rows: [
      new TableRow({ children: [
        headerCell('Treatment', 1, COLORS.headerBg),
        headerCell('PSP', 1, COLORS.pspDark),
        headerCell('CBD', 1, COLORS.cbdDark),
        headerCell('MSA', 1, COLORS.msaDark),
        headerCell('DLB', 1, COLORS.dlbDark),
      ]}),
      new TableRow({ children: [
        cell('Levodopa', { bg: COLORS.neutral, bold: true }),
        cell('Partial/transient benefit in ~30%', { bg: COLORS.psp }),
        cell('Rarely helpful', { bg: COLORS.cbd }),
        cell('MSA-P: minimal; MSA-C: none', { bg: COLORS.msa }),
        cell('Partial; may worsen psychosis', { bg: COLORS.dlb }),
      ]}),
      new TableRow({ children: [
        cell('Cholinesterase inhibitor', { bg: COLORS.neutral, bold: true }),
        cell('Not indicated', { bg: COLORS.psp }),
        cell('Not indicated', { bg: COLORS.cbd }),
        cell('Not indicated', { bg: COLORS.msa }),
        cell('Rivastigmine (FDA-approved for PDD; off-label DLB)', { bg: COLORS.dlb }),
      ]}),
      new TableRow({ children: [
        cell('Autonomic management', { bg: COLORS.neutral, bold: true }),
        cell('Mild measures', { bg: COLORS.psp }),
        cell('Mild measures', { bg: COLORS.cbd }),
        cell('Fludrocortisone, midodrine, compression stockings', { bg: COLORS.msa }),
        cell('Compression stockings, fluids', { bg: COLORS.dlb }),
      ]}),
      new TableRow({ children: [
        cell('Psychosis management', { bg: COLORS.neutral, bold: true }),
        cell('Careful; avoid haloperidol', { bg: COLORS.psp }),
        cell('Careful', { bg: COLORS.cbd }),
        cell('Careful', { bg: COLORS.msa }),
        cell('AVOID conventional antipsychotics!\nQuetiapine / clozapine only if essential', { bg: COLORS.dlb, bold: true }),
      ]}),
      new TableRow({ children: [
        cell('RBD management', { bg: COLORS.neutral, bold: true }),
        cell('N/A', { bg: COLORS.psp }),
        cell('N/A', { bg: COLORS.cbd }),
        cell('Clonazepam / melatonin', { bg: COLORS.msa }),
        cell('Clonazepam / melatonin', { bg: COLORS.dlb }),
      ]}),
      new TableRow({ children: [
        cell('Myoclonus', { bg: COLORS.neutral, bold: true }),
        cell('Clonazepam', { bg: COLORS.psp }),
        cell('Clonazepam (common in CBD)', { bg: COLORS.cbd }),
        cell('N/A', { bg: COLORS.msa }),
        cell('N/A', { bg: COLORS.dlb }),
      ]}),
      new TableRow({ children: [
        cell('Supportive care', { bg: COLORS.neutral, bold: true }),
        cell('Fall prevention, feeding support, speech therapy', { bg: COLORS.psp }),
        cell('PT/OT for apraxia, speech therapy', { bg: COLORS.cbd }),
        cell('CPAP/BiPAP for stridor, bladder catheterisation', { bg: COLORS.msa }),
        cell('Structured environment, caregiver support', { bg: COLORS.dlb }),
      ]}),
      new TableRow({ children: [
        cell('Disease-modifying therapy', { bg: COLORS.neutral, bold: true }),
        cell('None available', { bg: COLORS.psp, italic: true }),
        cell('None available', { bg: COLORS.cbd, italic: true }),
        cell('None available', { bg: COLORS.msa, italic: true }),
        cell('None available', { bg: COLORS.dlb, italic: true }),
      ]}),
    ],
  }),
];

// ── SECTION 7: References ─────────────────────────────────────────────────────
const referencesSection = [
  blankLine(),
  sectionTitle('REFERENCES', HeadingLevel.HEADING_1),
  bodyPara('1. Bradley WG, Daroff RB. Bradley and Daroff\'s Neurology in Clinical Practice, 8th ed. Elsevier, 2022.'),
  bodyPara('2. Kumar V, Abbas AK, Aster JC. Robbins & Cotran Pathologic Basis of Disease, 10th ed. Elsevier, 2023.'),
  bodyPara('3. Goldman L, Schafer AI. Goldman-Cecil Medicine, International Edition, 2-Volume Set. Elsevier, 2022.'),
  bodyPara('4. McKeith IG et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88-100.'),
  bodyPara('5. Gilman S et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670-676.'),
  bodyPara('6. Bruno MK et al. A General Neurologist\'s Practical Diagnostic Algorithm for Atypical Parkinsonian Disorders. Neurol Clin Pract. 2024 Dec. PMID: 39185098.'),
  bodyPara('7. Keir G et al. Atypical Parkinsonian Syndromes: Structural, Functional, and Molecular Imaging Features. AJNR. 2024 Dec. PMID: 39209485.'),
];

// ── Assemble Document ─────────────────────────────────────────────────────────
const doc = new Document({
  styles: {
    default: {
      document: {
        run: { font: 'Calibri', size: 18 },
      },
    },
  },
  sections: [
    {
      properties: {
        page: {
          margin: { top: 720, bottom: 720, left: 900, right: 900 },
        },
      },
      headers: {
        default: new Header({
          children: [
            new Paragraph({
              alignment: AlignmentType.RIGHT,
              children: [
                new TextRun({
                  text: "Parkinson's Plus Syndromes — Diagnostic Reference",
                  size: 16, color: '888888', font: 'Calibri',
                }),
              ],
            }),
          ],
        }),
      },
      footers: {
        default: new Footer({
          children: [
            new Paragraph({
              alignment: AlignmentType.CENTER,
              children: [
                new TextRun({ text: 'Page ', size: 16, color: '888888', font: 'Calibri' }),
                new PageNumber(),
                new TextRun({ text: ' | Orris Medical Reference', size: 16, color: '888888', font: 'Calibri' }),
              ],
            }),
          ],
        }),
      },
      children: [
        ...titleSection,
        ...flowchartSection,
        ...comparisonSection,
        ...summarySection,
        ...redFlagsSection,
        ...treatmentSection,
        ...referencesSection,
      ],
    },
  ],
});

Packer.toBuffer(doc).then(buffer => {
  fs.writeFileSync('/home/daytona/workspace/parkinson-plus/Parkinsons_Plus_Diagnostic_Flowchart.docx', buffer);
  console.log('Done.');
});

Running Command

cd /home/daytona/workspace/parkinson-plus && node generate.js 2>&1

Editing File

~/parkinson-plus/generate.js

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/parkinson-plus/generate.js'

Running Command

cd /home/daytona/workspace/parkinson-plus && node generate.js 2>&1

Running Command

python /home/daytona/skills/docx/scripts/office/validate.py /home/daytona/worksp…

Running Command

ls -lh /home/daytona/workspace/parkinson-plus/Parkinsons_Plus_Diagnostic_Flowcha…

Your document is ready:

Parkinsons Plus Diagnostic Flowchart

Word Document · DOCX

Here is what the document contains across its 5 sections:

Section 1 - Diagnostic Flowchart A step-by-step algorithm:

Step 1: Confirm parkinsonism (bradykinesia + rigidity/tremor/instability)
Decision point: Are red flags present? - table maps each flag to the syndrome it suggests
Step 2: Levodopa trial - sustained response favours PD; poor/absent response points to P+ syndrome
Step 3: Neuroimaging - "hummingbird sign" (PSP), "hot cross bun sign" (MSA-C), putaminal changes (MSA-P), DaT-SPECT/MIBG (DLB)

Section 2 - Master Comparison Table 20 rows covering molecular basis, pathological hallmark, onset age, sex, tremor, falls, eye movements, autonomic dysfunction, dementia, hallucinations, cognitive fluctuations, RBD, levodopa response, neuroleptic sensitivity, MRI findings, DaT-SPECT, MIBG, and prognosis - colour-coded per syndrome (blue/PSP, green/CBD, yellow/MSA, red/DLB).

Section 3 - Individual Syndrome Profiles Dedicated tables for PSP, CBD, MSA, and DLB covering pathology, core clinical triad, distinguishing features, evaluation, and management.

Section 4 - Red Flags Against Idiopathic PD 14 red flags mapped to their clinical significance, colour-coded in pink.

Section 5 - Treatment Overview Side-by-side treatment grid (levodopa, cholinesterase inhibitors, autonomic management, psychosis, RBD, myoclonus, supportive care) with the critical DLB antipsychotic warning highlighted.

This is a shared conversation. Sign in to Orris to start your own chat.